Ask AI
ProCE Banner Activity

HERTHENA-Lung02: Phase III Trial of Patritumab Deruxtecan (HER3-DXd) vs Chemotherapy in EGFRm Advanced NSCLC After a 3rd-Generation EGFR TKI

Conference Coverage
Slideset

In the randomized phase III HERTHENA-Lung02 trial, HER3-DXd statistically significantly improved PFS but not OS while exhibiting intracranial antitumor activity vs traditional platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC previously treated with a 3rd-generation EGFR TKI. 

Released: June 03, 2025

Expiration: December 02, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Inc, Genentech, a member of the Roche Group, and PharmaMar.

AstraZeneca

Boehringer Ingelheim Pharmaceuticals, Inc.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group

PharmaMar